Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen

Transplantation Proceedings

Volumn 43, Issue 4, 2011, Pages 1017-1019

  Mecule A ^a   Tinti, F ^a   Bachetoni, A ^a   Poli, L ^a   D'Alessandro, M ^a   Alessandri, C ^a   Umbro, I ^a   Nofroni, I ^a   Berloco, P B ^a   Mitterhofer, A P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 2; TACROLIMUS;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIET; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERLEUKIN-2; ITALY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957615115     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.02.047     Document Type: Conference Paper

References (12)

1. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 66:1736, 1998
2. Alloway R, Steinberg S, Khahil K, et al: Conversion of stable kidney transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified-release tacrolimus-based regimen. Transplant Proc 37:867, 2005
3. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al: Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 9:2505, 2009
4. Crespo M, Mir M, Marin M, et al: De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 41:2115, 2009
5. Borra LC, Roodnat JI, Kal JA, et al: High within-patient variability in the clearance of tacrolimus is a risk factor for poor long term outcome after kidney transplantation. Nephrol Dial Transplant 25:2757, 2010
6. Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623, 2004
7. Wang J, Zeevi A, McCurry K, et al: Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 nonexpressors. Transpl Immunol 15:235, 2006
8. Nankivell BJ, Borrows RJ, Fung CL, et al: Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 78:242, 2004
9. Veronese FV, Noronha IL, Manfro RC, et al: Prevalence immunohistochemical findings of subclinical kidney allograft rejectionand its association with graft outcome. Clin Transplant 18:357, 2004
10. Lauzurica R, Pastor MC, Bayes B, et al: Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus. Transplant Proc 39:2170, 2007
11. Mecule A, Poli L, Nofroni I, et al: Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc 42:1317, 2010
12. De Jonge H, Kuypers DR, Verbeke K, et al: Reduced C0 concentration and increased dose requirement in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 90:523, 2010